Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) CEO Anthony S. Marucci acquired 11,500 shares of the company's stock in a transaction dated Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Celldex Therapeutics Trading Up 3.1 %
Shares of Celldex Therapeutics stock opened at $27.01 on Wednesday. Celldex Therapeutics, Inc. has a 12-month low of $24.43 and a 12-month high of $53.18. The firm's 50-day moving average price is $33.29 and its two-hundred day moving average price is $35.72.
Institutional Investors Weigh In On Celldex Therapeutics
Large investors have recently bought and sold shares of the company. Novo Holdings A S grew its stake in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after buying an additional 113,663 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company's stock valued at $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Swiss National Bank boosted its stake in shares of Celldex Therapeutics by 17.8% in the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company's stock valued at $4,797,000 after purchasing an additional 17,300 shares in the last quarter. Bellevue Group AG boosted its stake in shares of Celldex Therapeutics by 15.7% in the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company's stock valued at $117,374,000 after purchasing an additional 380,319 shares in the last quarter. Finally, AlphaCentric Advisors LLC boosted its stake in shares of Celldex Therapeutics by 23.4% in the 2nd quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company's stock valued at $1,758,000 after purchasing an additional 9,000 shares in the last quarter.
Analyst Ratings Changes
When it comes to NVDA… “acceleration cycles” are the key
From DTI | Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options…
By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)...
And thanks to many months and late nights working out the kinks of the systems…
They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!
CLDX has been the topic of several research analyst reports. Citigroup initiated coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They issued a "buy" rating and a $70.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, November 7th. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They set a "neutral" rating and a $45.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Finally, Wolfe Research lowered shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.25.
View Our Latest Analysis on Celldex Therapeutics
Celldex Therapeutics Company Profile
(
Get Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
